Table 1

Characteristics of long-term survivors of childhood cancer with subsequent leukemia > 15 years from diagnosis

Primary diagnosisSubsequent leukemia subtypeTime to subsequent leukemia, yCytogeneticsPrimary therapy
Vital statusTime from subsequent leukemia to death, y
Radiation site and doseChemotherapy and cumulative dose (if known)
Hodgkin lymphoma T-cell large granular leukemia 31 T-cell gene rearrangements; cytogenetics: normal NA NA Alive NA 
Rhabdomyosarcoma AML-M1 31 Normal Pelvis 3450 cGy Actinomycin-D 0.48 mg/kg Dead 5.8 
Hodgkin lymphoma Leukemia NOS 25 Unknown Inverted Y 3600 cGy CPM 4650 mg/m2 Procarbazine 850 mg/m2 Doxorubicin 430 mg/m2 Dead 0.4 
Astrocytoma AML-M1 25 Normal Brain 5000 cGy No chemotherapy received Dead 1.6 
Wilms tumor T-cell ALL 21 Unknown NA NA Dead 0.8 
Fibrosarcoma Pre-B ALL 19 p53 mutation 0 cGy Doxorubicin 146 mg/m2 CPM 1825 mg/m2 Vincristine Dead 2 
ALL APL 19 t(15;17) 0 cGy L-Asparaginase 6-mercaptopurine Methotrexate, vincristine, prednisone Alive NA 
Ewing sarcoma Pre-B ALL 19 Unknown Chest 4500 cGy CPM 11 800 mg/m2 Doxorubicin 492 mg/m2 Actinomycin-D 0.34 mg/kg Alive NA 
Hodgkin lymphoma MDS/AML 18 Monosomy 7 Inverted Y 3600 cGy No chemotherapy received Alive NA 
Neuroblastoma MDS/AML 18 t(3;5) NA NA Dead 2.3 
Ewing sarcoma APL 16 t(15;17) 0 cGy CPM 12 000 mg/m2 Doxorubicin 480 mg/m2 Alive NA 
Hodgkin lymphoma AML 16 7q-, t(15;17) Mantle 1500 cGy Nitrogen mustard 50 mg/m2 Doxorubicin 198 mg/m2 Bleomycin 150 mg/m2 Procarbazine 4423 mg/m2 Dead 1.3 
Osteosarcoma ALL 15 46, xx, der(4) t(1;4)(q11;p16), t(9;16), t(9;22)(q34;q11.2) 0 cGy CPM 9200 mg/m2 Cisplatin 635 mg/m2 Doxorubicin 459 mg/m2 Actinomycin-D 0.28 mg/kg Bleomycin 123 mg/m2 Methotrexate 36 875 mg/m2 Dead 1.5 
Primary diagnosisSubsequent leukemia subtypeTime to subsequent leukemia, yCytogeneticsPrimary therapy
Vital statusTime from subsequent leukemia to death, y
Radiation site and doseChemotherapy and cumulative dose (if known)
Hodgkin lymphoma T-cell large granular leukemia 31 T-cell gene rearrangements; cytogenetics: normal NA NA Alive NA 
Rhabdomyosarcoma AML-M1 31 Normal Pelvis 3450 cGy Actinomycin-D 0.48 mg/kg Dead 5.8 
Hodgkin lymphoma Leukemia NOS 25 Unknown Inverted Y 3600 cGy CPM 4650 mg/m2 Procarbazine 850 mg/m2 Doxorubicin 430 mg/m2 Dead 0.4 
Astrocytoma AML-M1 25 Normal Brain 5000 cGy No chemotherapy received Dead 1.6 
Wilms tumor T-cell ALL 21 Unknown NA NA Dead 0.8 
Fibrosarcoma Pre-B ALL 19 p53 mutation 0 cGy Doxorubicin 146 mg/m2 CPM 1825 mg/m2 Vincristine Dead 2 
ALL APL 19 t(15;17) 0 cGy L-Asparaginase 6-mercaptopurine Methotrexate, vincristine, prednisone Alive NA 
Ewing sarcoma Pre-B ALL 19 Unknown Chest 4500 cGy CPM 11 800 mg/m2 Doxorubicin 492 mg/m2 Actinomycin-D 0.34 mg/kg Alive NA 
Hodgkin lymphoma MDS/AML 18 Monosomy 7 Inverted Y 3600 cGy No chemotherapy received Alive NA 
Neuroblastoma MDS/AML 18 t(3;5) NA NA Dead 2.3 
Ewing sarcoma APL 16 t(15;17) 0 cGy CPM 12 000 mg/m2 Doxorubicin 480 mg/m2 Alive NA 
Hodgkin lymphoma AML 16 7q-, t(15;17) Mantle 1500 cGy Nitrogen mustard 50 mg/m2 Doxorubicin 198 mg/m2 Bleomycin 150 mg/m2 Procarbazine 4423 mg/m2 Dead 1.3 
Osteosarcoma ALL 15 46, xx, der(4) t(1;4)(q11;p16), t(9;16), t(9;22)(q34;q11.2) 0 cGy CPM 9200 mg/m2 Cisplatin 635 mg/m2 Doxorubicin 459 mg/m2 Actinomycin-D 0.28 mg/kg Bleomycin 123 mg/m2 Methotrexate 36 875 mg/m2 Dead 1.5 

NOS indicates not otherwise specified; CPM, cyclophosphamide; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; and APL, acute promyelocytic leukemia.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal